Canada · Delayed Price · Currency is CAD Cybin Company Description
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.
It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.
The company is headquartered in Toronto, Canada.
| Country | Canada |
| Industry | Pharmaceutical Preparations |
| Employees | 50 |
| CEO | Eric So |
Contact Details
Address: 100 King Street West Toronto, ON M5X 1C9 Canada | |
| Website | cybin.com |
Stock Details
| Ticker Symbol | HELP |
| Exchange | Cboe Canada |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| ISIN Number | CA23256X4075 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric So | Chief Executive Officer |
| Greg Cavers | Chief Financial Officer |
| Aaron Bartlone | Chief Operating Officer |